Press Releases


June 8, 2016
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH


November 9, 2015
NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD’s The Liver Meeting® 2015

September 30, 2015
NGM Bio is named one of FierceBiotech’s “Fierce 15” Biotech Companies of 2015

March 24, 2015
NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine

March 23, 2015
NGM Biopharmaceuticals Secures $57.5 Million Series D Financing

March 2, 2015
NGM Biopharmaceuticals Announces Expansion of Management Team 

February 23, 2015
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics 
Link to webcast: NGM and Merck Webcast


July 18, 2013
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity

June 17, 2013
NGM Biopharmaceuticals and MedImmune, AstraZeneca’s Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity

January 3, 2013
NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes


March 28, 2012
NGM and Daiichi Sankyo Collaborate to Discover and Develop Innovative Therapeutics for Diabetes


October 4, 2010
NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director

March 15, 2010
NGM Biopharmaceuticals Raises $51 Million in Series B Financing and Appoints New Board Member


October 21, 2009
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors 

September 1, 2009
NGM Biopharmaceuticals Appoints Helen S. Kim as Chief Business Officer 


February 11, 2008
NGM Biopharmaceuticals, Inc. Raises $25.5M